COMP <GO>
DRMA vs ENLV // ENTERPRISE SCALE & MARKET CAP
Dermata Therapeutics Inc. (NASDAQ) VS. Enlivex Ltd. (NASDAQ) • 15-METRIC TALLY: DRMA 1
— ENLV 3
▲ ENTERPRISE SCALE & MARKET CAP LEADER: DRMA
LAST: $0.84 (-3.84%) • MKT CAP: $4.2M
market-cap
$4.2M
LAST: $2.54 (-2.68%) • MKT CAP: $3.9M
market-cap
$3.9M
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DRMA VS. ENLV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DRMA | ENLV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -0.60% | -34.40 | ENLV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 3/9 | -2.00 | ENLV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 39.9 | 65.3 | -25.50 | ENLV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $4.2M | $3.9M | $276.6K | DRMA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DRMA REV | ENLV REV | DRMA GROSS % | ENLV GROSS % | DRMA FCF | ENLV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$7.8M | -$10.5M |
| FY 2024 | $0 | $0 | — | — | -$11.2M | -$13.1M |
| FY 2023 | $0 | $0 | — | — | -$6.4M | -$23.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DRMA // BETA —
ENLV // BETA —